Abstract
The C group apolipoproteins are primarily associated with triglyceriderich lipoprotein particles (1). They are important in triglyceride metabolism where they act as allosteric affectors of lipoprotein lipase. Apolipoprotein C-II is an activator of lipoprotein lipase while C-III is an inhibitor of both lipoprotein lipase and hepatic lipase. Apolipoprotein C-III may also be involved in the receptor mediated uptake of triglyceriderich lipoproteins. Genetically determined deficiency of C-II is associated with a functional deficiency of lipoprotein lipase and severe hypertriglyceridemia (2). Menzel, et al (3) have reported a protein polymorphism in APO C-II in U.S. Blacks that involved the substitution of glutamine for lysine at residue 55 of the C-II polypeptide chain. They reported a frequency of 12% for this variant in a sample of 50 normolipidemic U.S. Blacks. Sepehrnia, et al (4) confirmed the presence of this polymorphism in U.S. Blacks, demonstrated its presence in Nigerians, and verified an autosomal codominant pattern of segregation in families. Reports of genetic variation in apolipoprotein C-III are restricted to two types of rare families. One having combined apolipoprotein A-I/C-III deficiency due to a sequence inversion involving both the APO A-I and C-III genes (5). Deficient family members have abnormalities of triglyceride metabolism that are corrected by the infusion of normal C-III (6). The second variant is recognized by unusually high levels of unglycosylated APO C-III (APO C-III0) due to the replacement of threonine by alanine at position 74 of the polypetide chain, which prevents 0-glycosylation (7). The latter mutation is not assocociated with gross alteration in lipoprotein levels.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
J.L. Breslow, Apolipoprotein genetic variation and human disease, Physiological Rev. 68:85 (1988).
W.C. Breckenridge, J.A. Little, G. Steiner, A. Chow, and M. Poapst, Hypertriglyceridemia associated with deficiency of apolipoprotein C-II, N. Eng. J. Med. 298:1265 (1978).
H.J. Menzel, J.P. Kane, M.J. Malloy, and R.J. Havel, A variant primary structure of apolipoprotein C-II in individuals of African descent, J. Clin, Invest. 77:595 (1986).
B. Sepehrnia, M.I. Kamboh, and R.E. Ferrell, Genetic studies of human apolipoproteins. JII. Polymorphism of apolipoprotein C-II, Hum. Hered. (1988). In press.
S.K. Karathanasis, DNA inversion inactivates both the apo Al and apo CIII gene in patients with combined apo Al and apo GUI deficiency and premature coronary artery disease. Circulation (Suppl. II) \ 74:157 (1986).
R. A. Narum, J.B. Lakier, S. Goldstein, A. Angel, R.B. Goldberg, W.D. Block, D.K. Noffze, P.J. Dolphin, J. Edelglass, D.D. Bogorad, and P. Alaupovic, Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease, N. Engl. J. Med. 306:1513 (1982).
H. Maeda, R.K. Hashimoto, T. Ogura, S. Hiraga, and H. Uzawa, Molecular cloning of a human APOC-III variant: Thr 74 Ala 74 mutation prevents O-glycosylation, J. Lipid Res. 28:1404 (1987).
M.I. Kamboh, R. E. Ferrell, and B. Sepehrnia, Genetic studies of human apolipoproteins. II.A. rapid one-dimensional isoelectric focusing technique to characterize apolipoproteins A-I, A-II, A-IV and C-II of unfractionated plasma, Electrophoresis 8:355 (1987).
Lipid Research Clinics Program. Manual of Laboratory Operations. Lipid and Lipoprotein Analysis (DHEW Publication No. M.I.H. 75-628) National Institutes of Health, Bethesda, MD. (1974).
G. Mancini, A. O. Carbonara, and J.F. Heremans, Immunochemical quantiation of antigens by single radial immunodiffusion, Immunoche 2:235 (1965).
E. Boerwinkle, R. Chakraborty, and C.F. Sing, The use of measured genotype information in the analysis of quantitative phenotypes in man. I. Models and analytical methods. Ann. Hum. Genet. 50:181 (1986).
C.G. Bhattacharya, A. simiple method of resolution of a distribution into Gaussian components, Biometrics 23:115 (1967).
R.A. Hegele, and J.L. Breslow, Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility. Genet. Epidemiol. 4:163 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Ferrell, R.E., Kamboh, M.I., Sepehrnia, B.S., Adams-Campbell, L.L., Weiss, K.M. (1988). Genetic Variation in the Apolipoproteins C-II and C-III. In: Malmendier, C.L., Alaupovic, P. (eds) Eicosanoids, Apolipoproteins, Lipoprotein Particles, and Atherosclerosis. Advances in Experimental Medicine and Biology, vol 243. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0733-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0733-4_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8055-2
Online ISBN: 978-1-4613-0733-4
eBook Packages: Springer Book Archive